deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02008227

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy

Sponsor: Hoffmann-La Roche

Conditions Non-Squamous Non-Small Cell Lung Cancer
Interventions Atezolizumab Docetaxel
Updated 15 times since 2017 Last updated: Dec 6, 2019 Started: Mar 11, 2014 Primary completion: Jul 7, 2016 Completion: Jan 9, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Non-Squamous Non-Small Cell Lung Cancer and is currently completed. Hoffmann-La Roche leads this study, which shows 15 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Jan 2018 · 5 months · monthly snapshot~Jan 2018 – ~May 2018 · 4 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Jan 2020 · 10 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2020 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 10 earlier versions

  1. Mar 2019 — Jan 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  6. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Aug 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Feb 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , A Coruña, Spain , Aichi, Japan , Athens, Greece , Atlanta, United States , Auckland, New Zealand , Austin, United States , Avellino, Italy , Aviano, Italy , Avignon, France and 173 more locations